US · IXHL
Incannex Healthcare Limited
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Sydney, NSW 2153
- Website
- incannex.com.au
Price · as of 2025-06-30
$4.55
Market cap 48.7M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $157.27 | +3,356.48% |
| Intrinsic Value(DCF) | $6.30 | +38.46% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $19.97 | ||||
| 2013 | $0.00 | $113.03 | |||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | ||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $0.00 | $22.26 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $566.40 | $255.94 | |||
| 2023 | $159.60 | ||||
| 2024 | $49.80 | $0.00 | $0.00 | ||
| 2025 | $15.75 | $157.27 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Incannex Healthcare Limited's (IXHL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $157.27
- Current price
- $4.55
- AI upside
- +3,356.48%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.30
+38.46% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IXHL | Incannex Healthcare Limit… | $4.55 | 48.7M | +3,356% | +38% | — | — | -0.39 | 1.35 | 210.33 | -0.07 | -0.04 | 1.35 | 100.00% | -27661.63% | -54517.44% | -381.09% | -1055.21% | -250.09% | 0.02 | -78.51 | 2.86 | 2.82 | 0.31 | 109298.00% | 37870.00% | -2234.00% | -69.22% | -1.79 | -577.00% | 0.00% | 0.00% | 51.39% | -0.14 | -0.26 | 38.46 | -12.32 |
| AGEN | Agenus Inc. | $3.33 | 113.25M | +151% | -72% | — | +7,590% | -0.22 | -0.15 | 0.49 | -1.04 | — | -0.14 | -50.79% | -116.44% | -219.61% | 95.45% | 58.03% | -86.00% | -0.29 | -1.02 | 0.21 | 0.18 | -0.54 | -2298.00% | -3381.00% | -3214.00% | -314.88% | -0.72 | 76.54% | 0.00% | 0.00% | 0.00% | -0.87 | -0.66 | 1.01 | -15.68 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| SCLX | Scilex Holding Company | $8.21 | 70.13M | +4,776% | -41% | — | — | -1.16 | -0.44 | 1.49 | -1.78 | — | -0.35 | 70.51% | -147.37% | -128.66% | 39.83% | 80.83% | -74.96% | -0.20 | -42.48 | 0.16 | 0.11 | -0.52 | -5668.00% | 2107.00% | -19198.00% | 22.92% | 0.07 | -18.75% | 0.00% | 0.00% | 106.43% | -1.43 | 6.16 | 2.10 | -13.47 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| STSS | Sharps Technology, Inc. | $1.73 | 50.16M | — | — | — | — | -0.04 | 0.19 | — | -0.48 | -0.01 | 0.19 | 0.00% | — | — | -187.23% | -159.55% | -97.33% | 1.89 | -4.61 | 0.61 | 0.19 | -0.42 | 78195.00% | — | -2322.00% | -1894.69% | -1.34 | -144.00% | 0.00% | 0.00% | 0.00% | -0.42 | -0.46 | — | -10.43 |
| SXTC | China SXT Pharmaceuticals… | $2.28 | 1.95M | +6,431% | +5,777% | — | +346% | -35.58 | 7.61 | 67.52 | -39.03 | -27.55 | 7.62 | 21.11% | -153.97% | -189.77% | -22.50% | -189.29% | -14.75% | 0.06 | -4.14 | 3.54 | 3.33 | 6.65 | 12913.00% | -973.00% | 2130.00% | -2.00% | -0.39 | -165.76% | 0.00% | 0.00% | 6.54% | -37.47 | -42.78 | 57.69 | 10.04 |
| TTRX | Turn Therapeutics Inc. | $3.60 | 106M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 3858.47% | 179.80% | -87.06% | -0.68 | — | 1.55 | 1.23 | 0.43 | — | — | 273.00% | — | -1.92 | 146.15% | — | 0.00% | — | — | — | — | — |
| ZYBT | Zhengye Biotechnology Hol… | $0.80 | 37.91M | +7,505% | — | — | — | — | — | — | — | — | — | 48.99% | 8.82% | 6.07% | 4.84% | 4.42% | 2.71% | 0.30 | 4.07 | 1.31 | 0.80 | 1.59 | — | -1195.00% | -6372.00% | — | 0.30 | 3.81% | — | 119.00% | — | — | — | — | — |
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
- CEO
- Joel Bradley Latham
- Employees
- 9
- Beta
- 2.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.30 ÷ $4.55) − 1 = +38.46% (DCF, example).